Australian Equity Indices

Points Change % Change Value Volume
S&P/ASX 200 5,531.0 + 13.2 + 0.24% $ 4,984,585,390.0 612,615,161.0
S&P/ASX 200
ALL ORDINARIES 5,515.5 + 13.3 + 0.24% $ 5,078,392,741.0 763,659,965.0
ALL ORDINARIES
S&P/ASX 100 4,598.1 + 10.3 + 0.22% $ 4,617,196,856.0 437,185,370.0
S&P/ASX 100
SMALL ORDS 2,192.3 + 8.5 + 0.39% $ 422,575,309.0 233,820,527.0
S&P/ASX SMALL ORDINARIES
advertising

Market Summary

Price % Chg
TSE TFIELDSERV $ 0.890 + 5.95%
TEN TEN NET $ 0.275 + 5.77%
GEM G8 EDUCATE $ 4.820 + 5.70%
GFF GOODMAN $ 0.550 + 4.76%
RSG RESOLUTE $ 0.645 + 4.03%
MGX MT GIBSON $ 0.770 - 3.75%
WSA WEST AREAS $ 4.310 + 3.36%
RMD RESMED $ 5.260 + 3.14%
BDR BEADELL $ 0.665 + 3.10%
NST NTH STAR $ 1.175 + 3.07%

Commodities

Price Change % Chg
BRENT SPOT (USD/BBL) 109.120 0.000 0.00%
LIGHT CRUDE JUN4 (USD/BBL) 101.990 + 0.550 + 0.54%
NAT GAS MAY14 (USD/MMBTU) 4.700 - 0.030 - 0.63%
Bid Ask Bid Chg Bid % Chg
GOLD (USD/OZ) 1289.34 1290.56 + 6.05 + 0.47%
SILVER (USD/OZ) 19.62 19.67 + 0.22 + 1.13%
PLATINUM (USD/OZ) 1405.49 1413.00 + 8.89 + 0.64%
PALLADIUM (USD/OZ) 797.75 803.75 + 14.35 + 1.83%

Markets Data »

Currencies

AUD USD EUR JPY GBP
AUD AUD 0.9255 0.6693 94.73 0.5509
USD 1.0803 USD 0.7232 102.34 0.5953
EUR 1.4937 1.3825 EUR 141.51 0.8231
JPY 0.0106 0.0098 0.0071 JPY 0.0058
GBP 1.8142 1.6794 1.2145 171.88 GBP

Markets Data »

Stock price lookup

Shares

Banks lift stocks to near six-year highs

Vesna Poljak | The Australian sharemarket finished the week up 1.4 per cent as bank stocks helped the S&P/ASX 200 Index to close to a six-year high and the case for keeping interest rates on hold for the rest of 2014 firmed, buoying the in-favour banking sector.

Property

How to make money off the plan

Rebecca Thistleton | Australia is currently gripped by rapid sales of off-the-plan apartments, with new unit approvals hitting record levels.

Fixed Income

Japanese bonds to drive $A

Jonathan Shapiro | Asset shift at world’s largest pension fund could exacerbate pressure on the Australian dollar.

Specialist Investments

Market Intelligence

Superannuation

Should couples pool their super?

Debra Cleveland | A pooled joint account would ensure similar focus on nest eggs as on the rest of their household finances.

New Investor

| Shares in Atrum Coal surged more than 7 per cent on Friday, unsupported by newsflow - but don’t be surprised if that emerges as early as next week. Our snouts say that’s when the all-important prefeasibility study regarding on Groundhog project in British Columbia could be released. Atrum has traditionally been conservative with its estimates, so don’t be surprised if this creates substantial interest in the stock. The PFS could potentially be the green light for the project, but more importantly, it will flesh out the value of the resource and the estimated mine life. Atrum is definitely one to put on the watchlist, with news likely to emerge mid-week, possibly pre-empted by a trading halt. It may be wise to get set when the market opens on Monday.

New Investor

| Jaws dropped at AMP HQ late last week on news of Queensland adviser Rhys Wood’s submission to the Financial System Inquiry. Wood, who is the director of a financial planning company licensed by AMP, accused groups of directing advisers to use in-house products. But it must have been a misunderstanding, or a reference to some other institution, because we’ve heard Wood say in the past that he “doesn’t feel any pressure to sell AMP products”. In fact, it turns out he joined AMP early last year because of its focus on “acting in the best interests of clients”. Looking at closely at AMP’s approved products list, which includes more than 550 investment options, only 192 or a little more than one-third are AMP branded. Who says there’s a problem?

New Investor

| The savage sell down of biotech stock QRxPharma has many investors talking about the quality of the sector’s analysts, with one in particular coming under particular scrutiny. The analyst has been talking up a handful of prospects recently, including QRxPharma, which fell 80 per cent after US authorities knocked back its product MOXDUO, a combination of potent painkillers morphine and oxycodone. The analyst hadn’t considered that possibility (despite two pervious knock backs) and earlier this month told clients that the FDA’s upcoming meeting would simply “discuss and recommend MOXDUO”. Smart Investor spoke to a fund manager who recently sold his entire biotech holdings, citing this particular analyst as a reason for losing faith in the sector. A little too close to the company, perhaps?

My Watchlists

You need to be logged in to see your watchlists.

My Portfolios

You need to be logged in to see your portfolios.